Exploiting fucoxanthin mono-carrier nanoparticles to modulate digestion and metabolic regulation in an obesity model DOI
Xin Zhang,

Jianjun Dong,

Yin Hua

и другие.

Food Bioscience, Год журнала: 2023, Номер 57, С. 103466 - 103466

Опубликована: Дек. 17, 2023

Язык: Английский

Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management DOI Open Access
Sukanya Pati, Wadeed Irfan, Ahmed Tariq Jameel

и другие.

Cancers, Год журнала: 2023, Номер 15(2), С. 485 - 485

Опубликована: Янв. 12, 2023

Obesity or excess body fat is a major global health challenge that has not only been associated with diabetes mellitus and cardiovascular disease but also risk factor for the development of mortality related to subgroup cancer. This review focuses on epidemiology, relationship between obesity recurrence cancer management obesity.

Язык: Английский

Процитировано

331

Healthy Lifestyle and Cancer Risk: Modifiable Risk Factors to Prevent Cancer DOI Open Access
Pasquale Marino,

Mariangela Mininni,

Giovanni Deiana

и другие.

Nutrients, Год журнала: 2024, Номер 16(6), С. 800 - 800

Опубликована: Март 11, 2024

Cancer has become a serious problem worldwide, as it represents the main cause of death, and its incidence increased over years. A potential strategy to counter growing spread various forms cancer is adoption prevention strategies, in particular, use healthy lifestyles, such maintaining weight, following diet; being physically active; avoiding smoking, alcohol consumption, sun exposure; vitamin D supplementation. These modifiable risk factors are associated with this disease, contributing development, progression, severity. This review evaluates relationship between potentially overall specifically breast, colorectal, prostate cancer, highlights updated recommendations on prevention. The results numerous clinical epidemiological studies clearly show influence lifestyles development cancer. An incorrect diet, composed mainly saturated fats processed products, resulting body combined physical inactivity, induced an increase all three types under study. Given importance adopting correct prevent global institutions should develop strategies environments that encourage individuals adopt regular behaviors.

Язык: Английский

Процитировано

65

Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024 DOI Creative Commons
Harold Bays, Carol F. Kirkpatrick, Kevin C. Maki

и другие.

Journal of clinical lipidology, Год журнала: 2024, Номер 18(3), С. e320 - e350

Опубликована: Апрель 24, 2024

BACKGROUNDThis joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk.METHODSThis is based upon scientific evidence, perspectives authors, peer OMA NLA leadership.RESULTSAmong individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles.CONCLUSIONSObesity increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. Among patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD. This risk. leadership. particles.

Язык: Английский

Процитировано

27

Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024 DOI Creative Commons
Harold Bays, Carol F. Kirkpatrick, Kevin C. Maki

и другие.

Obesity Pillars, Год журнала: 2024, Номер 10, С. 100108 - 100108

Опубликована: Март 12, 2024

This joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk. is based upon scientific evidence, perspectives authors, peer OMA NLA leadership. Among individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles. increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD.

Язык: Английский

Процитировано

19

Gut Microbiome and Its Impact on Obesity and Obesity-Related Disorders DOI
Senthilkumar Sankararaman,

Kimberly Janelle Noriega,

Sujithra Velayuthan

и другие.

Current Gastroenterology Reports, Год журнала: 2022, Номер 25(2), С. 31 - 44

Опубликована: Дек. 5, 2022

Язык: Английский

Процитировано

50

Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023 DOI Creative Commons
Harold Bays,

Shagun Bindlish,

Tiffany Lowe Clayton

и другие.

Obesity Pillars, Год журнала: 2023, Номер 5, С. 100056 - 100056

Опубликована: Янв. 28, 2023

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of type 2 diabetes mellitus (T2DM), obesity-related cardiometabolic risk factor.

Язык: Английский

Процитировано

32

A narrative review: CXC chemokines influence immune surveillance in obesity and obesity-related diseases: Type 2 diabetes and nonalcoholic fatty liver disease DOI Open Access
Amin Ullah,

Ahmad Ud Din,

Wen Ding

и другие.

Reviews in Endocrine and Metabolic Disorders, Год журнала: 2023, Номер 24(4), С. 611 - 631

Опубликована: Март 31, 2023

Язык: Английский

Процитировано

28

Lycopene: A Potent Antioxidant with Multiple Health Benefits DOI Creative Commons
Mercy Omoye Shafe,

Nontobeko Myllet Gumede,

Trevor Tapiwa Nyakudya

и другие.

Journal of Nutrition and Metabolism, Год журнала: 2024, Номер 2024(1)

Опубликована: Янв. 1, 2024

Lycopene is a naturally occurring carotenoid predominantly found in tomatoes and tomato‐based products. Like other phytochemicals, it exhibits health beneficial biological activities that can be exploited when used as dietary supplement. In vitro vivo , lycopene has been demonstrated to mitigate oxidative stress‐induced metabolic dysfunctions diseases including inflammation, obesity, diabetes mellitus. shown alleviate affect the bone, eye, kidney, liver, lungs, heart, nervous system. This review presents state of art regarding lycopene’s benefits its potential applications system delivery. Furthermore, protective effects against toxins, safety use, possible toxicity are explored.

Язык: Английский

Процитировано

13

Harnessing Nanotechnology for Idarubicin Delivery in Cancer Therapy: Current Approaches and Future Perspectives DOI
Fatemeh Safari,

Yeganeh Jalalian,

Hamidreza Abdouss

и другие.

BioNanoScience, Год журнала: 2024, Номер 14(4), С. 4108 - 4130

Опубликована: Апрель 11, 2024

Язык: Английский

Процитировано

7

Thirty Obesity Myths, Misunderstandings, and/or Oversimplifications: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 DOI Creative Commons
Harold Bays, Angela Golden, Justin Tondt

и другие.

Obesity Pillars, Год журнала: 2022, Номер 3, С. 100034 - 100034

Опубликована: Авг. 10, 2022

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of 30 common obesity myths, misunderstandings, and/or oversimplifications. The scientific support for this CPS based upon published citations, clinical perspectives OMA authors, and peer review by the leadership. discusses oversimplifications, utilizing referenced publications such as integrative use other CPSs help explain applicable physiology/pathophysiology. on oversimplifications one a series designed assist in care patients with disease obesity. Knowledge underlying science may medicine clinician improve

Язык: Английский

Процитировано

26